Arena Pharmaceuticals' (ARNA) Lorcaserin Proposed for DEA Schedule IV
Tweet
Share
E-mailGet Alerts ARNA Hot Sheet
Join SI Premium – FREE
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) is seeing activity after its Lorcaserin was proposed for DEA Schedule IV placement. Link
The Drug Enforcement Administration (DEA) proposes placing the substance lorcaserin, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible, into Schedule IV of the Controlled Substances Act (CSA).
The Drug Enforcement Administration (DEA) proposes placing the substance lorcaserin, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible, into Schedule IV of the Controlled Substances Act (CSA).
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ocugen doses first patient in Phase 3 gene therapy trial for dry AMD
- BlossomHill to present BH-30643 trial data at lung cancer conference
- Cytokinetics aficamten shows cardiac benefits in two HCM trial analyses
Create E-mail Alert Related Categories
FDA, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
